Berry Genomics Co

Berry Genomics Co Book Value Growth

The Book Value Growth of Berry Genomics Co (000710.SZ) as of Oct 21, 2026 is -12.10 %. In the previous year, Book Value Growth was -9.90 % — a change of 22.22% (lower).

Book Value Growth

-12.10 %

YoY

22.22%

Last updated:

Book Value Growth of Berry Genomics Co is 2025 -12.10 % . Book Value Growth of Berry Genomics Co was 2024 -9.90 % . It decreases by 22.22% lower compared to the previous year.

The Berry Genomics Co Book Value Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value Growth
Date
Book Value Growth
Jan 1, 2018
23.88 CNY
Jan 1, 2019
22.33 CNY
Jan 1, 2020
2.58 CNY
Jan 1, 2021
4.26 CNY
Jan 1, 2022
-7.58 CNY
Jan 1, 2023
-19.00 CNY
Jan 1, 2024
-9.90 CNY
Jan 1, 2025
-12.10 CNY
The Berry Genomics Co Book Value Growth history
YEARBook Value GrowthYoY
-12.10 %+22.22%
-9.90 %-47.90%
-19.00 %+150.64%
-7.58 %-277.97%
4.26 %+65.20%
2.58 %-88.45%
22.33 %-6.50%
23.88 %-98.09%
1,246.97 %-40,718.96%
-3.07 %-67.65%
-9.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Berry Genomics Co Stock analysis

What does Berry Genomics Co do? Berry Genomics Co., Ltd. generates revenue through basic scientific research services, medical testing services, and the sale of reagents and equipment. The company provides transcriptome sequencing, human whole exome sequencing, and whole genome sequencing for scientific research clients. Medical testing services include tumor genetic testing, genetic disease testing, and reproductive health testing for healthcare providers. Reagent and equipment sales feature the NextSeq CN500 gene sequencer and general reagents for sequencing reactions, targeting research institutions and medical facilities. The primary buyers of basic scientific research services are research institutions requiring advanced sequencing platforms. Medical testing services are purchased by healthcare providers offering diagnostic solutions. Reagent and equipment sales target both research and medical sectors, with the NextSeq CN500 gene sequencer being a key product for high-throughput sequencing needs. The company's revenue streams are segmented by service type, with research services and medical testing forming the core business segments. Berry Genomics' product portfolio includes sequencing platforms, testing reagents, and equipment like the NextSeq CN500 gene sequencer. These products serve research institutions and medical facilities, with medical testing services focusing on tumor, genetic disease, and reproductive health applications. The company's sales strategy emphasizes high-throughput sequencing technology solutions for both scientific and medical markets. Berry Genomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Berry Genomics Co stock

Book Value Growth of Berry Genomics Co is -12.10 % in 2025.

On Eulerpool you can find the complete historical development of Book Value Growth Berry Genomics Co since 2006 – with annual values, charts, and detailed analysis.

Book value growth measures the percentage increase in shareholders' equity. It indicates how effectively the company retains and grows its net assets.

To evaluate Book Value Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Book Value Growth.

Book Value Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Book Value Growth's Berry Genomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Berry Genomics Co

All Key Metrics — Berry Genomics Co